the ApoB/Lp(a)/VLDL thread that’s bouncing around longevity right now is worth pulling on specifically for people running GLP-1s or tirz, because the lipid panel most clinics default to isn’t the one that tells you what’s happening on these compounds. quick frame on what each measures, because the conflation is constant: - LDL-C is a calculated estimate of cholesterol mass inside LDL particles. one number, derived, not measured directly in standard panels.
- ApoB counts particles. every atherogenic particle (LDL, VLDL, IDL, Lp(a), chylomicron remnants) carries exactly one ApoB-100 or ApoB-48 molecule, so ApoB is a particle count, not a mass.
- Lp(a) is genetically determined, largely fixed for life, and worth measuring once. it’s not a tracking variable, it’s a baseline risk flag.
- VLDL carries triglycerides and matters more on metabolically active interventions because it shifts with insulin sensitivity and hepatic fat turnover. the relevant point for tirz specifically: tirzepatide moves LDL-C and ApoB in directions that don’t always agree. you can have falling LDL-C and rising ApoB if particle number is going up while particles get smaller and denser, and the standard panel will read as improvement while atherogenic burden is actually worse. small dense LDL is what you don’t want, and LDL-C alone can’t see it. what I run now and why: - ApoB instead of LDL-C as the primary tracking number. one particle count beats a calculated mass estimate, full stop.
- Lp(a) once, baseline, then never again unless something changes biologically.
- VLDL or triglycerides as a separate lever, because GLP-1/GIP effects on hepatic TG output are part of the mechanism story and worth tracking independently.
- pre-start panel, then repeat at 12 weeks. modeled on TRT lipid monitoring cadence, which is the closest analogue for a metabolically active compound that moves lipids in variable directions. the part I’d push on for anyone running tirz or sema and not measuring ApoB: “my LDL went down” is not a clean signal on these compounds. it’s a partial signal that can mask particle-count drift in either direction. imo the bigger gap in the longevity-lipid discussion is that nobody is pairing ApoB with where the patient is in dose-ramp on a GLP-1. early ramp is high GI side effects and disrupted sleep, both of which move hepatic metabolism, both of which move VLDL and ApoB. a 12-week post-titration draw is a cleaner read than anything during titration. ymmv but this is the panel I’d ask for before another LDL-C alone.
the “12-week post-titration draw is a cleaner read” point is the one I’d staple to every endo’s door. my February A1C draw landed right at peak GI disruption on dose ramp, and in retrospect I was malnourished enough week-to-week that any lipid panel from that window was junk. ApoB specifically needs hepatic metabolism to be somewhere close to baseline or you’re measuring a moving target. one thing I’d add that’s missing from this frame: VLDL on tirz moves faster than ApoB in my data, and the two diverge early. triglycerides were down ~30% by week 8 when ApoB hadn’t shifted meaningfully yet, which matches the GIP-mediated hepatic fat mechanism running ahead of the particle-count story. so if you’re running both, VLDL/trigs give you an early signal and ApoB gives you the 12-week confirmation. treating them as redundant is where people drop one off the panel and lose the timing information.
the part I’d push on is calling VLDL and ApoB an “early signal / 12-week confirmation” pair, because I think that frames them as the same measurement at different timepoints when they’re actually tracking different physiology. VLDL/trig drop at week 8 is hepatic TG output falling, which is mostly a fat-mass and hepatic-fat-turnover story driven by GIP-mediated insulin sensitivity. ApoB at week 12 is particle count across the whole atherogenic pool, which integrates LDL receptor activity, hepatic ApoB secretion, and remnant clearance. those two can move in opposite directions on the same compound and still both be “true” reads of what’s happening, they’re just answering different questions. the steel-man on your framing is real, in your data they tracked sequentially and the early VLDL move did predict where ApoB landed at 12 weeks. ime that sequencing isn’t reliable across users though. I’ve seen reports where trigs drop hard in the first 6-8 weeks and ApoB barely moves at 12 or even drifts up, because particle number didn’t follow the TG story, it followed a small-dense-LDL shift instead. so “early signal, confirmed later” undersells how much they can diverge in direction, not just timing. where I’d actually agree is on not dropping either from the panel. but the reason isn’t redundancy with a lag, it’s that they answer different questions and you need both to read what tirz is doing. trigs/VLDL tell you about hepatic fat and TG turnover, ApoB tells you about atherogenic particle burden. treating one as a preview of the other is how people end up surprised when the 12-week ApoB doesn’t match what the 8-week trig drop seemed to promise.
“treating one as a preview of the other is how people end up surprised” – the framing of “surprised” is where I’d actually push back. the steel-man is real: VLDL/trig and ApoB are measuring genuinely different physiology and collapsing them into a predictive timeline is imprecise in exactly the way you describe. but “surprised when the 12-week ApoB doesn’t match what the 8-week trig drop seemed to promise” implies the trig drop was making a claim it couldn’t keep. if you go into the panel knowing that trigs tell you hepatic fat is moving and ApoB tells you whether atherogenic particle burden followed, the trig drop isn’t promising anything about ApoB, it’s confirming one mechanism fired. the divergence you’re describing isn’t the trig signal being false, it’s two independent signals being read as one. my more practical complaint is separate from yours: the “12-week draw” framing is doing enormous work in this whole conversation and almost nobody factors in where they are in dose ramp when they pull it. week 12 at 5mg is not the same metabolic state as week 12 at 10mg or 15mg. I was still titrating at 12 weeks, which means my ApoB at that draw was reading a system actively in transition, not a post-titration steady state. that’s the part I’d want the protocol to name explicitly before recommending the timing.